Loading
companiesCompany
Telix Pharmaceuticals
Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.
Overview
Telix Pharmaceuticals, based in Melbourne and listed as TLX.AX, is the Australian theranostics company behind the Illuccix and Gozellix kits for gallium-68 PSMA-11 imaging and a broad therapeutic pipeline. TLX250-CDx, or zirconium-89 girentuximab for carbonic anhydrase IX PET in kidney cancer, received an FDA complete response letter in 2025, TLX591, or lutetium-177 rosopatamab, a PSMA antibody in the ProstACT phase 3, and TLX101 for glioma follow. OnCo links it to prostate cancer and renal cell carcinoma, to PSMA as a target, to CAIX PET and PET tracer manufacturing, and to the idea of CAIX theranostics pairing girentuximab imaging with lutetium or actinium therapy. Whether an antibody-based PSMA therapy can compete with small-molecule ligands is the open question. Illuccix has its own page.
Headquarters
Melbourne, AU
Scorecard
All companies#167of 1244 companies, score 34
- approved products +12
- phase 3 +3
- targets +2
- modalities +2
- regions +5
- registry trials +10
2 approved, 1 in phase 3, 0 earlier, 1 targets, 23 registry studies. Formula on the scorecards page.
Type
Radiopharmaceuticals · TLX.AX
Stage
Public
Website
Phase 3PET imaging antibody labelled with zirconium-89
Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.
ApprovedPET imaging agent
Gallium-68 gozetotide (PSMA-11) · Illuccix / Gozellix / Locametz
Gallium-68 PSMA-11 was the first PSMA PET tracer approved in the US (2020), and is made on site from a generator or cyclotron.
ApprovedPET imaging agent kit (PSMA, gallium-68)
Illuccix (kit for Ga-68 gozetotide) · Illuccix / Gozellix
Telix's ready-to-label kit that lets any nuclear medicine department make the gallium PSMA scan for prostate cancer.
Similar pages
- CompanyPETNET Solutions (Siemens Healthineers)
Shares PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyLantheus
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares PET tracer manufacturing and distribution, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays.
- TreatmentLocametz (kit for Ga-68 gozetotide)
Shares Gallium-68 gozetotide (PSMA-11), Illuccix (kit for Ga-68 gozetotide), PSMA, Prostate cancer.
- Key paperDiagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial
Shares Gallium-68 gozetotide (PSMA-11), Illuccix (kit for Ga-68 gozetotide), PSMA, Prostate cancer.
- Key paper[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
Shares CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy, CAIX PET (89Zr-girentuximab).
- TrialPSMA-PreRP
Shares Gallium-68 gozetotide (PSMA-11), Illuccix (kit for Ga-68 gozetotide), PSMA, Prostate cancer.
- CompanyCurium
Shares Radionuclide generators and cold kits, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Radiopharmaceutical GMP and releasing a drug that decays, Prostate cancer.
cancers
fronts
technologies
targets
drugs
ApprovedPET imaging agent
Gallium-68 gozetotide (PSMA-11) · Illuccix / Gozellix / Locametz
ApprovedPET imaging agent kit (PSMA, gallium-68)
Illuccix (kit for Ga-68 gozetotide) · Illuccix / Gozellix
Phase 3PET imaging antibody labelled with zirconium-89
trials
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyPSMA PET Combined With MRI for the Detection of PCaStudy of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)